Iron as Therapeutic Targets in Human Diseases Volume 1
Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | Book Chapter |
| Published: |
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 08938naaaa2202677uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_50679 | ||
| 005 | 20210211 | ||
| 020 | |a books978-3-03928-083-4 | ||
| 020 | |a 9783039280827 | ||
| 020 | |a 9783039280834 | ||
| 024 | 7 | |a 10.3390/books978-3-03928-083-4 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 100 | 1 | |a Gozzelino, Raffaella |4 auth | |
| 700 | 1 | |a Poli, Maura |4 auth | |
| 700 | 1 | |a Arosio, Paolo |4 auth | |
| 245 | 1 | 0 | |a Iron as Therapeutic Targets in Human Diseases Volume 1 |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (472 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a developmental | ||
| 653 | |a Anemia of chronic disease | ||
| 653 | |a neurodegeneration | ||
| 653 | |a supplementation | ||
| 653 | |a MHC | ||
| 653 | |a iron chelation therapy | ||
| 653 | |a osteoblast | ||
| 653 | |a serum biomarker | ||
| 653 | |a FeSO4 | ||
| 653 | |a haptoglobin | ||
| 653 | |a prevention | ||
| 653 | |a brain development | ||
| 653 | |a pituitary | ||
| 653 | |a trauma | ||
| 653 | |a hepcidin | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a chaotropes | ||
| 653 | |a social behavior | ||
| 653 | |a Africa | ||
| 653 | |a macrophage | ||
| 653 | |a anemia of inflammation | ||
| 653 | |a Tfr2 | ||
| 653 | |a chelation | ||
| 653 | |a cardiomyocyte | ||
| 653 | |a IV iron therapy | ||
| 653 | |a Oxidative stress | ||
| 653 | |a treatment | ||
| 653 | |a chronic kidney disease | ||
| 653 | |a iron homeostasis | ||
| 653 | |a oxygen sensing | ||
| 653 | |a iron chelators | ||
| 653 | |a age-related macular degeneration (AMD) | ||
| 653 | |a pharmaceutical targets | ||
| 653 | |a non-transferrin-bound iron (NTBI) | ||
| 653 | |a iron dextran | ||
| 653 | |a pulmonary arterial hypertension | ||
| 653 | |a labile iron | ||
| 653 | |a low and middle income countries | ||
| 653 | |a ferroportin | ||
| 653 | |a gut microbiota | ||
| 653 | |a reducibility | ||
| 653 | |a non-HFE | ||
| 653 | |a oxidative stress | ||
| 653 | |a antitumor compound | ||
| 653 | |a senescence | ||
| 653 | |a electron transfer | ||
| 653 | |a nanotechnology | ||
| 653 | |a iron deficiency | ||
| 653 | |a neonatal period | ||
| 653 | |a heme oxygenase | ||
| 653 | |a hypoxia | ||
| 653 | |a Anemia | ||
| 653 | |a NCOA4 | ||
| 653 | |a patient blood management | ||
| 653 | |a microbiome | ||
| 653 | |a anemia | ||
| 653 | |a iron mobilization | ||
| 653 | |a iron release | ||
| 653 | |a phlebotomy | ||
| 653 | |a peritoneal dialysis | ||
| 653 | |a Friedreich Ataxia | ||
| 653 | |a ferritin | ||
| 653 | |a CD8+ T cells | ||
| 653 | |a M cells | ||
| 653 | |a neurodegenerative disease | ||
| 653 | |a NaFeEDTA | ||
| 653 | |a vascular calcification | ||
| 653 | |a cinnamic acid derivatives | ||
| 653 | |a oral iron salts | ||
| 653 | |a lipid | ||
| 653 | |a acute lung injury | ||
| 653 | |a Iron-sulfur | ||
| 653 | |a Interleukin-6 | ||
| 653 | |a neurodegeneration with brain iron accumulation | ||
| 653 | |a macrophages | ||
| 653 | |a erythroblastic islands | ||
| 653 | |a cystic fibrosis | ||
| 653 | |a neuroimmune responses | ||
| 653 | |a flavin nucleotide | ||
| 653 | |a hemopexin | ||
| 653 | |a Iron chelators | ||
| 653 | |a nutrient iron | ||
| 653 | |a developing countries | ||
| 653 | |a hereditary hypoferritinemia | ||
| 653 | |a iron | ||
| 653 | |a cancer | ||
| 653 | |a Indonesia | ||
| 653 | |a n/a | ||
| 653 | |a Hfe | ||
| 653 | |a HFE | ||
| 653 | |a chronic heart failure | ||
| 653 | |a iron supplementation | ||
| 653 | |a intestinal inflammation | ||
| 653 | |a TNF | ||
| 653 | |a chelators | ||
| 653 | |a hemolysis | ||
| 653 | |a children | ||
| 653 | |a pulmonary arterial smooth muscle cells | ||
| 653 | |a cytokines | ||
| 653 | |a didox | ||
| 653 | |a intravenous iron | ||
| 653 | |a T lymphocytes | ||
| 653 | |a colorectal cancer | ||
| 653 | |a infants | ||
| 653 | |a liver | ||
| 653 | |a ferritinophagy | ||
| 653 | |a hereditary hyperferritinemia | ||
| 653 | |a SCFA | ||
| 653 | |a rheumatoid arthritis | ||
| 653 | |a membrane interactions | ||
| 653 | |a Sucrosomial® iron | ||
| 653 | |a lung | ||
| 653 | |a Kupffer cell | ||
| 653 | |a iron chelation | ||
| 653 | |a erythrophagocytosis | ||
| 653 | |a acute kidney injury | ||
| 653 | |a neurophysiology | ||
| 653 | |a iron transporters | ||
| 653 | |a iron absorption | ||
| 653 | |a infection | ||
| 653 | |a ferroptosis | ||
| 653 | |a fluorescent iron chelator | ||
| 653 | |a neonatal | ||
| 653 | |a SNC | ||
| 653 | |a immunity | ||
| 653 | |a mycobacteria | ||
| 653 | |a non-haem iron | ||
| 653 | |a natural history | ||
| 653 | |a 3-hydroxy-4-pyridinone | ||
| 653 | |a haem | ||
| 653 | |a inflammation | ||
| 653 | |a bone homeostasis | ||
| 653 | |a cardiovascular disease | ||
| 653 | |a heme | ||
| 653 | |a heme homeostasis | ||
| 653 | |a protein binding | ||
| 653 | |a brain | ||
| 653 | |a iron deficiency anemia | ||
| 653 | |a Fe2+-chelating activity | ||
| 653 | |a bioengineering | ||
| 653 | |a Mek/Erk | ||
| 653 | |a Bmp/Smad | ||
| 653 | |a iron delivery | ||
| 653 | |a genetic hemochromatosis | ||
| 653 | |a osteoclast | ||
| 653 | |a histidine | ||
| 653 | |a rhodamine | ||
| 653 | |a COPD | ||
| 653 | |a hemorrhage | ||
| 653 | |a antibacterial activity | ||
| 653 | |a bacteria | ||
| 653 | |a SLC40A1 | ||
| 653 | |a transferrin receptor | ||
| 653 | |a drug delivery | ||
| 653 | |a nanocage | ||
| 653 | |a soybean seed ferritin | ||
| 653 | |a pig | ||
| 653 | |a iron metabolism | ||
| 653 | |a kidney | ||
| 653 | |a innate immunity | ||
| 653 | |a cataracts syndrome | ||
| 653 | |a erythropoiesis | ||
| 653 | |a obesity | ||
| 653 | |a mucosal immunity | ||
| 653 | |a iron overload | ||
| 653 | |a fluorophore | ||
| 653 | |a binding ability | ||
| 653 | |a inflammatory bowel disease (IBD) | ||
| 653 | |a osteoporosis | ||
| 653 | |a biomarker | ||
| 653 | |a bioavailability | ||
| 653 | |a adverse event profile | ||
| 653 | |a metabolism | ||
| 653 | |a iron-carbohydrate complex | ||
| 653 | |a kinetics | ||
| 653 | |a flavonoids | ||
| 653 | |a iron regulatory proteins | ||
| 653 | |a lung infection | ||
| 653 | |a non transferrin bound iron | ||
| 653 | |a central nurse macrophage | ||
| 653 | |a iron processing | ||
| 653 | |a malaria | ||
| 653 | |a neurodegenerative diseases | ||
| 653 | |a multifunctional iron chelators | ||
| 653 | |a retina | ||
| 653 | |a neuroinflammation | ||
| 653 | |a anti-hepcidin therapy | ||
| 653 | |a lung diseases | ||
| 653 | |a anaemia | ||
| 653 | |a RRM2 | ||
| 653 | |a cognition | ||
| 653 | |a mitochondria | ||
| 653 | |a therapy | ||
| 653 | |a NBIA | ||
| 653 | |a red pulp macrophage | ||
| 653 | |a efficacy | ||
| 653 | |a hemochromatosis | ||
| 653 | |a tolerability | ||
| 653 | |a oral iron therapy | ||
| 653 | |a growth | ||
| 653 | |a venesections | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2016 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/50679 |7 0 |z DOAB: description of the publication |